CLOV insider sale notice: 2,012 shares via Morgan Stanley

Rhea-AI Filing Summary

Clover Health Investments, Corp. (CLOV) Form 144 notice records a proposed sale of 2,012 common shares with an aggregate market value of $5,271.44 through Morgan Stanley Smith Barney LLC on 10/07/2025. The shares were acquired as Restricted Stock Units and delivered on 10/03/2025, with the original grant year shown as 2012. The issuer reports 420,139,394 shares outstanding. The filing also discloses two prior 10b5-1 sales by Jamie Reynoso totaling 11,737 shares for gross proceeds of approximately $34,936.45 on 08/04/2025 and 09/17/2025. The filer certifies no undisclosed material adverse information and notes potential reliance on a trading plan.

Positive

• Shares sold are small relative to outstanding shares: 2,012 vs 420,139,394
• Proceeds stem from RSUs vested on 10/03/2025, indicating planned compensation realization

Negative

• Insider sales continued: two prior 10b5-1 sales totaled 11,737 shares for ~$34,936.45
• Proposed sale filed under Form 144 may indicate ongoing dilution or planned disposals by insiders

Insights

Insider Transactions Analyst

TL;DR: A newly vested RSU sale of $5,271.44 is modest versus the company's outstanding shares; prior 10b5-1 sales totaled $34,936.45.

The transaction shows a proposed brokered sale of 2,012 shares acquired as Restricted Stock Units on 10/03/2025

While the absolute dollar amounts are small relative to 420,139,394 shares outstanding, investors typically watch insider sales patterns; two prior 10b5-1 sales by Jamie Reynoso (on 08/04/2025 and 09/17/2025) combined for 11,737 shares and about $34,936.45. Monitor whether future filings show continued systematic sales under a trading plan within the next few months.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/07/2025 - 04:20 PM Learn about SEC filing dates

FAQ

What does the CLOV Form 144 report?

It reports a proposed sale of 2,012 common shares valued at $5,271.44 to be executed on 10/07/2025 through Morgan Stanley Smith Barney LLC.

Who acquired the securities being sold?

The shares were acquired as Restricted Stock Units and vested on 10/03/2025; the grant year on record is 2012.

How many CLOV shares are outstanding?

The filing lists 420,139,394 shares outstanding.

Were there recent insider sales for CLOV?

Yes. Two 10b5-1 sales for Jamie Reynoso on 08/04/2025 and 09/17/2025 sold 6,823 and 4,914 shares respectively, totaling 11,737 shares and about $34,936.45 gross.

Which broker will execute the proposed sale?

The broker named is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	2012	5271.44	420139394	10/07/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/03/2025	Restricted Stock Units	Issuer			2012	10/03/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for JAMIE REYNOSO 1209 Orange Street Wilmington DE 19801	Common	09/17/2025	4914	15218.66
10b5-1 Sales for JAMIE REYNOSO 1209 Orange Street Wilmington DE 19801	Common	08/04/2025	6823	19717.79

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)